\BOOKMARK [1][-]{section.1}{Project Scope}{}% 1
\BOOKMARK [2][-]{subsection.1.1}{Aims and Objectives}{section.1}% 2
\BOOKMARK [2][-]{subsection.1.2}{Stakeholders and their Interests}{section.1}% 3
\BOOKMARK [2][-]{subsection.1.3}{Methods of Communication}{section.1}% 4
\BOOKMARK [2][-]{subsection.1.4}{Project Infrastructure}{section.1}% 5
\BOOKMARK [2][-]{subsection.1.5}{Installation Standards and Procedures}{section.1}% 6
\BOOKMARK [2][-]{subsection.1.6}{Quality Checks}{section.1}% 7
\BOOKMARK [1][-]{section.2}{Project Specification}{}% 8
\BOOKMARK [2][-]{subsection.2.1}{Deliverables}{section.2}% 9
\BOOKMARK [2][-]{subsection.2.2}{Risk Analysis}{section.2}% 10
\BOOKMARK [1][-]{section.3}{Product Description}{}% 11
\BOOKMARK [2][-]{subsection.3.1}{Purpose}{section.3}% 12
\BOOKMARK [2][-]{subsection.3.2}{Product Derivation}{section.3}% 13
\BOOKMARK [2][-]{subsection.3.3}{Product Composition and Form}{section.3}% 14
\BOOKMARK [2][-]{subsection.3.4}{Relevant Standards}{section.3}% 15
\BOOKMARK [1][-]{section.4}{Literature Review}{}% 16
\BOOKMARK [2][-]{subsection.4.1}{Drug Discovery and Design}{section.4}% 17
\BOOKMARK [2][-]{subsection.4.2}{CNS Drug Design and the Blood Brain Barrier}{section.4}% 18
\BOOKMARK [3][-]{subsubsection.4.2.1}{ADME Properties of CNS Drugs}{subsection.4.2}% 19
\BOOKMARK [2][-]{subsection.4.3}{Machine Learning in Drug Discovery and Design}{section.4}% 20
\BOOKMARK [1][-]{section.5}{Conclusion}{}% 21
\BOOKMARK [1][-]{section.6}{Annotated Bibliography}{}% 22
\BOOKMARK [2][-]{subsection.6.1}{Big data: The future of biocuration}{section.6}% 23
\BOOKMARK [2][-]{subsection.6.2}{Introduction to Drug Discovery}{section.6}% 24
\BOOKMARK [2][-]{subsection.6.3}{Chemoinformatics: Concepts, Methods and Tools for Drug Discovery}{section.6}% 25
\BOOKMARK [2][-]{subsection.6.4}{Medicinal Chemical Properties of Successful Central Nervous System Drugs}{section.6}% 26
\BOOKMARK [2][-]{subsection.6.5}{Machine Learning approaches in Drug Discovery: methods and applications}{section.6}% 27
